MediqTrans Secures Translation Service Agreement with Haemophilia & Renal Leader for 36 Languages

MediqTrans to Drive Translation Service Best Practices, Agreement Expected to Drive 30% Cost Savings

MediqTrans today announced that it has secured a new, one year contract with a world-leading haemophilia and renal products company. Under this agreement, MediqTrans will be part of a small and select group of qualified global translation service providers for the company, and will deliver language support across multiple business units. MediqTrans will support all content types, including those categorised under Regulatory Affairs, Medical Affairs, Marketing, Training and Legal.

The client will rely on MediqTrans’ expertise in life sciences translation methodology and technology, global operating hub of 4,000 certified medical translators, and organization-wide ERP to drive translation compliance and cost savings for them.

“We’re excited and proud to have been assessed and appointed by one of the biggest and most well-known brands in the life sciences industry to be their translation services partner. Over the years, their employees have addressed translation needs through a hybrid mix of global multilingual, and also local monolingual, translation suppliers.”

“The challenges of achieving both quality compliance (as recognised by the company) and also cost optimization, are not fully addressed in either traditional global, or local suppliers.” said Chris Lim, Director, MediqTrans.

“With our validated approach and unique production model combining an extensive 5-step QA workflow, our breath of language options, and our focus on cost optimization through extensive technology deployment, we look forward to adding significant value, and being a trusted long-term partner for our client.”